These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35077845)

  • 1. Inhibition of celecoxib crystallization by mesoporous silica - Molecular dynamics studies leading to the discovery of the stabilization origin.
    Kramarczyk D; Knapik-Kowalczuk J; Smolka W; Monteiro MF; Tajber L; Paluch M
    Eur J Pharm Sci; 2022 Apr; 171():106132. PubMed ID: 35077845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Factors Governing the Liquid and Glassy States Recrystallization of Celecoxib in Binary Mixtures with Excipients of Different Molecular Weights.
    Grzybowska K; Chmiel K; Knapik-Kowalczuk J; Grzybowski A; Jurkiewicz K; Paluch M
    Mol Pharm; 2017 Apr; 14(4):1154-1168. PubMed ID: 28241116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Devitrification of amorphous celecoxib.
    Gupta P; Bansal AK
    AAPS PharmSciTech; 2005 Sep; 6(2):E223-30. PubMed ID: 16353981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterising glass transition temperatures and glass dynamics in mesoporous silica-based amorphous drugs.
    Kissi EO; Ruggiero MT; Hempel NJ; Song Z; Grohganz H; Rades T; Löbmann K
    Phys Chem Chem Phys; 2019 Sep; 21(35):19686-19694. PubMed ID: 31469369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amorphous Salts Solid Dispersions of Celecoxib: Enhanced Biopharmaceutical Performance and Physical Stability.
    Mukesh S; Joshi P; Bansal AK; Kashyap MC; Mandal SK; Sathe V; Sangamwar AT
    Mol Pharm; 2021 Jun; 18(6):2334-2348. PubMed ID: 34003656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enthalpy relaxation studies of celecoxib amorphous mixtures.
    Kakumanu VK; Bansal AK
    Pharm Res; 2002 Dec; 19(12):1873-8. PubMed ID: 12523668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of amorphous celecoxib stability by mixing it with octaacetylmaltose: the molecular dynamics study.
    Grzybowska K; Paluch M; Wlodarczyk P; Grzybowski A; Kaminski K; Hawelek L; Zakowiecki D; Kasprzycka A; Jankowska-Sumara I
    Mol Pharm; 2012 Apr; 9(4):894-904. PubMed ID: 22384922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dielectric study of the molecular mobility and the isothermal crystallization kinetics of an amorphous pharmaceutical drug substance.
    Alie J; Menegotto J; Cardon P; Duplaa H; Caron A; Lacabanne C; Bauer M
    J Pharm Sci; 2004 Jan; 93(1):218-33. PubMed ID: 14648651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between Molecular Mobility and Physical Stability in Pharmaceutical Glasses.
    Mehta M; Ragoonanan V; McKenna GB; Suryanarayanan R
    Mol Pharm; 2016 Apr; 13(4):1267-77. PubMed ID: 26895136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of molecular interaction in stability of celecoxib-PVP amorphous systems.
    Gupta P; Thilagavathi R; Chakraborti AK; Bansal AK
    Mol Pharm; 2005; 2(5):384-91. PubMed ID: 16196491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of Mesoporous Silica Particle Size in the Stabilization of Amorphous Pharmaceuticals-The Case of Simvastatin.
    Knapik-Kowalczuk J; Kramarczyk D; Chmiel K; Romanova J; Kawakami K; Paluch M
    Pharmaceutics; 2020 Apr; 12(4):. PubMed ID: 32331310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Physical Study of Three Pharmaceutically Active Benzodiazepine Derivatives: Crystalline versus Amorphous State and Crystallization Tendency.
    Valenti S; Barrio M; Negrier P; Romanini M; Macovez R; Tamarit JL
    Mol Pharm; 2021 Apr; 18(4):1819-1832. PubMed ID: 33689364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mobility of amorphous S-flurbiprofen: a dielectric relaxation spectroscopy approach.
    Rodrigues AC; Viciosa MT; Danède F; Affouard F; Correia NT
    Mol Pharm; 2014 Jan; 11(1):112-30. PubMed ID: 24215236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular-level insight into hot-melt loading and drug release from mesoporous silica carriers.
    Lizoňová D; Mužík J; Šoltys M; Beránek J; Kazarian SG; Štěpánek F
    Eur J Pharm Biopharm; 2018 Sep; 130():327-335. PubMed ID: 30012403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amorphous agomelatine stabilization in the presence of pyrogenic silica: Molecular mobility and intermolecular interaction studies.
    Barmpalexis P; Vardaka E; Moutafidis IM; Kachrimanis K
    Eur J Pharm Biopharm; 2019 Jun; 139():291-300. PubMed ID: 31026514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of Thermal Properties, Molecular Dynamics, and Physical Stability of Etoricoxib Mixtures with Octaacetylmaltose near the Glass Transition.
    Grzybowska K; Rams-Baron M; Łucak K; Grzybowski A; Paluch M
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stabilizing Unstable Amorphous Menthol through Inclusion in Mesoporous Silica Hosts.
    Cordeiro T; Castiñeira C; Mendes D; Danède F; Sotomayor J; Fonseca IM; Gomes da Silva M; Paiva A; Barreiros S; Cardoso MM; Viciosa MT; Correia NT; Dionisio M
    Mol Pharm; 2017 Sep; 14(9):3164-3177. PubMed ID: 28836790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of α-relaxation on crystallization of amorphous celecoxib above T(g) probed by dielectric spectroscopy.
    Dantuluri AK; Amin A; Puri V; Bansal AK
    Mol Pharm; 2011 Jun; 8(3):814-22. PubMed ID: 21534589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced oral delivery of celecoxib via the development of a supersaturable amorphous formulation utilising mesoporous silica and co-loaded HPMCAS.
    Lainé AL; Price D; Davis J; Roberts D; Hudson R; Back K; Bungay P; Flanagan N
    Int J Pharm; 2016 Oct; 512(1):118-125. PubMed ID: 27543354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relaxation Dynamics vs Crystallization Kinetics in the Amorphous State: The Case of Stiripentol.
    Ruiz GN; Romanini M; Barrio M; Tamarit JL; Pardo LC; Macovez R
    Mol Pharm; 2017 Nov; 14(11):3636-3643. PubMed ID: 28915351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.